# Toward a protective Covid-19 vaccine utilizing an established vector platform

> **NIH NIH R21** · THOMAS JEFFERSON UNIVERSITY · 2020 · $429,000

## Abstract

Abstract
The recently emerged coronavirus SARS-CoV-2, the causative agent of COVID-19, is rapidly spreading in the
world with over 4,8 million cases, and 320,000 deaths as of May 16, 2020. This novel coronavirus is thought to
have emerged from a live animal market in Wuhan, China. It has quickly spread in the community with large
clusters of human-to-human transmission. Sequencing of several isolates has determined that the most closely
related strains are SARS-like bat coronavirus lineages. The susceptibility of SARS-CoV-2 to anti-viral
compounds, its ability to replicate in cell lines or host factors regulating its replication are all currently unknown.
Importantly, there are no therapeutics available to treat the virus, although investigational studies are underway.
Modelling of the current outbreak suggests that the virus could infect >1 billion people and become a yearly
epidemic. Identifying people who have developed antibodies is important for the epidemiology as well as patient
care.
With the exponentially expounding threat of SARS-CoV-2 to global health, a vaccine is desperately needed.
Herein we propose the development of a novel, highly efficacious and safe COVID-19 vaccine with facile scale
up potential. Our proposal uses a rabies virus-based vector that has proven to be an efficient vaccine against
emerging and re-emerging infectious diseases. We have demonstrated that inactivated rabies virus particles
containing the coronavirus (CoV) spike S1 protein induce potent immune responses and provide protection in
animal systems against Middle Eastern Respiratory Syndrome coronavirus (MERS) and Severe Acute
Respiratory Syndrome (SARS) coronavirus, both of which are highly related to SARS-CoV-2. A similar vaccine
entitled CoraVax™ is available and herein we propose to analyze CoraVax™ immunogenicity in mice as well as
its abilty to protect in a hamster model.

## Key facts

- **NIH application ID:** 10170820
- **Project number:** 1R21AI158044-01
- **Recipient organization:** THOMAS JEFFERSON UNIVERSITY
- **Principal Investigator:** Matthias Johannes Schnell
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $429,000
- **Award type:** 1
- **Project period:** 2020-07-16 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10170820

## Citation

> US National Institutes of Health, RePORTER application 10170820, Toward a protective Covid-19 vaccine utilizing an established vector platform (1R21AI158044-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10170820. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*